

Chronic Kidney Disease

@ckd_ce on Twitter




Effect of Belimumab on Preventing de novo Renal Lupus Flares

@CKD_ce  · Oct 31, 2023




@ckd_ce · [Follow](#)


1a) Welcome to a  [#accredited](#) [#tweetorial](#) brought to you by the collaboration of [@ckd_ce](#) & [@KIReports](#). Our returning guest author is Subashri Mohanasundaram [@happiedoc](#), [#nephrologist](#) , Nephrology. Asst Prof, GTKMCH, Tuticorin.



@CKD_ce 

@ckd_ce · [Follow](#)

1b) Our topic for  CE/#CME : [#belimumab](#) and prevention of de novo [#renal_flare](#).
[#MedTwitter](#) [#nephtwitter](#) [@ISNkidneycare](#) [#lupus](#)
[@MedTweutorials](#)



Watch on X



GIF

5:57 AM · Oct 31, 2023



3



Reply



Copy link


[Read 1 reply](#)

@CKD_ce  · Oct 31, 2023



@ckd_ce · [Follow](#)

Replying to @ckd_ce

2a) This is part of a foundational 🍎 [#MedEd](#) [#accredited](#) series hosted by core [@ckd_ce](#) faculty [@sophia_kidney](#). See prior [#tweetorials](#), still available for  [CE/#CME](#) credit, at [ckd-ce.com](#), plus [#blogposts](#) edited by [@sophia_kidney](#) at [kireportscommunity.org](#).



kireportscommunity.org

Kidney Education | KI Reports Community

KI Reports Community is the blog page affiliated with KI Reports and the ISN, ...

@CKD_ce

@ckd_ce · [Follow](#)

2b) This program is intended for [#healthcare](#) professionals. Follow this to earn CE/[#CME](#) courtesy of the collaboration of [@ckd_ce](#) and [@KIReports](#). Faculty disclosures at [ckd-ce.com/](#)

@CKD_ce · Oct 31, 2023



@ckd_ce · [Follow](#)

Replying to @ckd_ce

2b) This program is intended for [#healthcare](#) professionals. Follow this to earn CE/[#CME](#) courtesy of the collaboration of [@ckd_ce](#) and [@KIReports](#). Faculty disclosures at [ckd-ce.com/disclosures/](#). There was no financial support provided by industry for this program.



ckd-ce.com

Disclosures | CKD CE

Faculty



...

@CKD_ce 

@ckd_ce · [Follow](#)

3) Let's start with [#MedHist](#)!

 It's always fascinating!

 In 1800s, Ferdinand von Hebra used the metaphor of a  to describe the classic [#malar](#) rash observed in systemic [#lupus](#) erythematosus ([#SLE](#))

5) 🧬 In the 1980s, it was demonstrated that [#cytotoxic](#) drugs + [#corticosteroids](#) stop the progression of [#renalfailure](#)

🧬 Inclusion of [#cyclophosphamide](#) increased patient survival to 80% after five years

👉 seminal article in [@nejm](#) at: <https://t.co/wObxoyVZki>

— @CKD_ce (@ckd_ce) [October 31, 2023](#)

5:57 AM · Oct 31, 2023



7) 🧬 Belimumab: a monoclonal antibody ([#mAb](#)) against B cell activating factor ([#BAFF](#))


👍 2 🗨️ Reply 🔗 Copy link






✅ First biological treatment for [#SLE](#) to be authorized, in 2011



✅ Subsequently approved for the tx of [#LN](#), Dec 2020, based on [#BLISS_LN](#), by Furie et al in [@nejm](#): <https://t.co/gqk15BYVQk> pic.twitter.com/BoKRsWrFCa

— @CKD_ce (@ckd_ce) [October 31, 2023](#)

9) Check out the beautiful [#visualabstract](#) by [@DrPSVali](#) on that article here:
pic.twitter.com/6F4V28KaRI
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

11)  Intervention: [#Belimumab](#) vs placebo, in addition to standard therapy (ST) for a duration as represented here: pic.twitter.com/eZeTcSVknw
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

13)  Results:
Of 1844 study participants with all trials combined
 602 received IV [#belimumab](#) 10 mg/kg
 311 received IV belimumab 1 mg/kg
 343 received SC belimumab
 588 study participants received placebo
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

15a)  Individuals who received IV [#belimumab](#) 1 mg/kg (non-licensed dose) 
lower proportion of de novo renal flares (4.2%) vs placebo-treated pts (8.7%; $P = 0.036$).
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

16) 🔥 Important predictors of renal flares: positive anti-[#dsDNA](#) and [#anticardiolipin](#) (IgA and IgG) antibodies pic.twitter.com/icvrYbNxdw
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

18) 🔍 [@IoannisParodis](#) et al hypothesized: de novo [#LN](#) cases tx'd w/ [#belimumab](#) may occur
!? Based on assumption that LN activation might result from drug's inhibition of regulatory B cell subsets
!? Serum IL-10 drops quickly, noticeably, & persistently upon beginning belimumab Rx
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

20) Conclusion:
🌟 Asian descent: vulnerable to new onset renal involvement
📌 In individuals with [#SLE](#) with no past history of LN;
🌟 low-dose IV 1 mg/kg & SC 200 mg [#belimumab](#) + nonbiological ST → protective against renal 🔥
🌟 permitted IV dose (10 mg/kg) → no obvious protection.
— @CKD_ce (@ckd_ce) [October 31, 2023](#)

22a) So let's review. According to British Isles Lupus Assessment Group (#BILAG), score E means:

a) active dz req'ing tx intensification

b) stable & mild dz



c) no current but history of involvement in that organ system

d) no history of or current involvement in that organ system

— @CKD_ce (@ckd_ce) [October 31, 2023](#)

23a) Which of the following #interleukins has been hypothesized to contribute to development of de novo #renal flares in patients treated with #belimumab?

— @CKD_ce (@ckd_ce) [October 31, 2023](#)

24) And you just earned 0.5hr  CE/#CME! Claim your certificate at <https://t.co/4vmLsTZ27l>. Thanks for following this ! Get more #MedEd #nephtwitter by FOLLOWING US here!

Thanks to guest faculty @happiedoc & series editor @sophia_kidney!#FOAMed #nephtwitter #lupustwitter

— @CKD_ce (@ckd_ce) [October 31, 2023](#)

Claim your 0.5h CE/CME Credit Here

Name *

First Name

Last Name

Email *

example@example.com

What best describes your title? *

- MD/DO
- RN/NP
- PA
- PharmD/RPh
- Respiratory Therapist
- Non-Clinician Research Coordinator
- Other

If MD/DO

- nephrologist
- endocrinologist
- cardiologist (heart failure)
- cardiologist (lipid/vascular)
- cardiologist (interventional)
- cardiologist (general)

- emergency medicine specialist
- critical care specialist
- hospitalist
- other internist
- primary care provider
- industry
- Other

If RN/NP

- NPP
- ICU
- cath lab
- ward
- clinic
- academic
- industry

Industry

Other

If PharmD

hospital/health system-based

community

academic

industry

Other

Where are you based?

EU/GB

Canada

USA

Latin America

Australia/NZ

Asia

How did you FIRST hear about our tweetorials?

- found it on Twitter searching in subject area
- found it on twitter searching for CE/CME
- found it on Twitter by following individual influencer
- found it on Twitter by following institutional influencer
- from LinkedIn

How many years have you been in practice?

How many patients per month do you typically see with the disease addressed in this tweetorial?

1. Which of the following interleukins has been hypothesized to contribute to development of de novo renal lupus flares in patients treated with belimumab? *

- a) Interleukin- 1
- b) Interleukin- 6
- c) Interleukin- 10
- d) Interleukin- 12

2. Did you follow the entire tweetorial? *

- Yes
- No

3. Did you find this to be an effective learning tool? *

- Yes
- No

4. On a scale of 1 to 5, how applicable to your clinical practice was the material in this tweetorial? *

1 2 3 4 5

Not At All Pertinent Extremely Pertinent

5. How will this program change your practice? *

- Not pertinent to my practice
- Reinforces my practice
- Makes me want additional education
- Will change my practice

6. Will you recommend @CKD_CE and/or this website to your colleagues? *

Yes

No

[Claim Certificate](#)



